Antiviral Pharmacology

The focus of the Antiviral Pharmacology group led by Anne-Grete Märtson is optimizing antiviral therapy for different viral infections by conducting clinical trials and using innovative computational and dynamic laboratory methodologies.

The research group focuses on optimizing antiviral drug dosing and therapy using computational modelling (PK/PD, PBPK modelling) and laboratory methods simulating human drug exposure (e.g., hollow-fibre infection model). We investigate the drug exposure-response relationships (PK/PD) to investigate what are the optimal targets for efficient therapy with least toxicity while preventing development of drug resistance. We conduct clinical studies, laboratory experiments and use computational methods to find best treatment regimens and translate results back to the clinical setting. 

Our research topics include optimizing ganciclovir therapy for cytomegalovirus (CMV), therapeutic drug monitoring of antivirals, relating antiviral drug exposure to dose-related toxicity, dosing in extremes of organ function and in special populations, delay in antiviral therapy in SARS-CoV-2.